Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Semaglutide, a glucagon-like peptide-1 receptor agonist, is linked with significant cardiorenal improvements and a favorable safety profile in adults with 

, with or without type 2 diabetes mellitus (T2DM).

Findings from a meta-analysis of 5 randomized controlled trials showed semaglutide significantly reduced the risk of major cardiovascular adverse events (MACE), kidney-related complications, and cardiovascular mortality, additionally pointing to the need to address gaps in the literature and enhance generalizability.

“Our findings advocate for semaglutide's role as a valuable therapeutic option for patients with CKD due to its demonstrated cardiovascular and renal benefits,”

wrote study investigator, Mahir Tesfaye from Addis Ababa University in Ethiopia, and colleagues.

 “The observed reduction in cardiovascular medication usage also means that semaglutide may decrease the need for intensive pharmacological interventions. This might improve patient quality of life, adherence, and healthcare costs.”

Standard treatment strategies for CKD include medication management of associated risk factors, such as hyperglycemia, dyslipidemia, and blood pressure. Recent cardiovascular outcome trials have highlighted renoprotective benefits and glucose-lowering effects in glucagon-like peptide-1 receptor agonists, but have been limited in sample size.

To address this gap in research, investigators conducted a systematic review of MEDLINE, Embase, and Cochrane CENTRAL databases to find studies comparing semaglutide with placebo or standard care in adults 18 ≥ years of age with CKD, regardless of comorbidity of type 2 diabetes mellitus status.

Primary outcomes included major kidney-related adverse events, MACE, cardiovascular mortality, nonfatal myocardial infarction (MI), and nonfatal stroke.

All-cause mortality, serious adverse events, hospitalization due to unstable angina or heart failure, and the use of cardiovascular medications were the secondary outcomes.

Investigators leveraged data from 12,785 participants with comorbid T2DM and CKD from 5 randomized controlled trials. The patient population had a mean age of 64-67 years, was predominantly male, with elevated body weight (~90–109 kg) and body mass index (~32–37 kg/m²), consistent blood pressure (systolic blood pressure ~135–138 mmHg; diastolic blood pressure ~76–78 mmHg) and glycemic control (Hemoglobin A1c ~5.6–8.7%).1

An outlier study, Apperloo, had a younger cohort, with a mean age of 55 years, and was the only trial with a completely non-diabetic CKD population, while the remaining studies enrolled 100% patients with T2DM.

Analysis of the pooled trial data revealed a significantly reduced risk of cardiovascular mortality compared with placebo, with a 26% relative risk reduction (Relative Risk [RR], 0.74; 95% Confidence Interval [CI], 0.62–0.88; I² = 36%).

Investigators observed a 22% reduced incidence of MACE (RR, 0.78; 95% CI, 0.70–0.87; I² = 0%), highlighting consistent cardiovascular benefit. While there was a trend toward reduction in nonfatal myocardial infarction and nonfatal stroke, these outcomes were not statistically significant (MI: RR, 0.86; 95% CI, 0.66–1.12; I² = 24%; stroke: RR, 0.86; 95% CI, 0.53–1.40; I² = 64%).

Kidney outcomes were similarly improved, with a 20% decrease in major kidney adverse events among patients receiving semaglutide (RR, 0.79; 95% CI, 0.71–0.87; I² = 0%).

For secondary outcomes, semaglutide showed a non-significant trend toward reduced all-cause mortality (RR, 0.80; 95% CI, 0.68–0.93; I² = 44%), and was associated with fewer serious adverse events (RR, 0.86; 95% CI, 0.74–0.99; I² = 87%). Sensitivity analysis further strengthened the effect on serious adverse events (RR, 0.92; 95% CI, 0.87–0.98; I² = 14%).

Investigators noted no significant differences in hospitalizations for unstable angina (RR, 1.01; 95% CI, 0.55–1.84; I² = 27%) or heart failure (RR, 1.03; 95% CI, 0.76–1.40; I² = 0%). The need for cardiovascular medications was modestly reduced, corresponding to a 14% relative risk reduction, with low heterogeneity.

“These findings are collectively supportive of its use as a therapeutic strategy for CKD management, with or without diabetes,” investigators concluded.

 “Long-term studies, however, are needed to confirm its role in reducing rates of hospitalization and mortality in broader populations of patients.”

Abdullah A, Sagreeka FNU, Aniket GA, et al. Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis. 

‌Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. 

https://doi.org/10.1038/s41581-020-00367-2

Caruso I, Giorgino F. SGLT2 inhibitors as cardio-renal protective agents. 

. Published online November 2021:154937. doi:

https://doi.org/10.1016/j.metabol.2021.154937

Articles

Semaglutide, a glucagon-like peptide-1 receptor agonist, demonstrates significant cardiorenal benefits and a favorable safety profile in adults with chronic kidney disease (CKD), with or without type 2 diabetes mellitus (T2DM). A meta-analysis of five randomized controlled trials revealed semaglutide's efficacy in reducing major cardiovascular adverse events (MACE), kidney-related complications, and cardiovascular mortality. The analysis also highlighted a reduction in cardiovascular medication usage, potentially improving patient quality of life and healthcare costs. Long-term studies are needed to confirm its broader impact on hospitalization and mortality rates.

Meta-analysis shows semaglutide lowers cardiovascular and kidney risks while supporting safety in adults with chronic kidney disease.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

, already a steadily rising dermatologic condition, will impact even more patients worldwide by 2050, with incidence increasing across age cohorts, sexes, and geographic regions.

These data were authored by investigators such as Linli Liu, MD, from the department of dermatology at Suining Central Hospital in China. Liu and coauthors described psoriasis as a long-standing inflammatory skin condition that continues to contribute substantially to global health challenges. They implemented data drawn from the Global Burden of Disease (GBD) Study 2021 to generate projections of worldwide psoriasis incidence through the year 2050.

Distinctions by age range, sex, and geographic region were particularly emphasized in their analysis, as prior research had not fully assessed these factors.

“Understanding these variations is critical for informing public health strategies, improving health care access, and supporting early diagnosis worldwide,” Liu and colleagues wrote.

The investigative team looked at information on psoriasis from 236 countries collected between 1990 - 2021, taken from the GBD Study 2021, assessing rates of prevalence, disease incidence, and disability-adjusted life-years (DALYs) reported by patients' sex, age, and geographic area. Through the use of an Autoregressive Integrated Moving Average (ARIMA) model, the team forecasted age-standardized incidence rates (ASIR) with 95% prediction intervals.

A sensitivity analysis was used by Liu et al to repeat the modeling after the removal of the 2021 data point and training the model on 1990 - 2020 alone. The investigators extended projections to 2050 and the connection between Sociodemographic Index (SDI) and psoriasis burden was assessed via a Spearman correlation. Additionally, ASIR–SDI links were visualized by Liu and colleagues using a scatterplot displaying 95% uncertainty intervals. All analyses were performed by the investigators in July 2025, with statistical significance being set at a 2-sided 

Globally, Liu and coauthors demonstrated a moderate rise between 1990 - 2021 in disease burden. ASIR rose among male patients from 56.89 to 62.77 cases per 100 000, representing a 10.3% increase. In female patients, the investigative team showed a growth in ASIR from 57.08 to 61.26 cases per 100 000, representing a 7.3% increase.

In their extension of the forecasts based on data through 2021, the team concluded ASIR would likely continue to climb, with roughly 70 per 100 000 in men and 66 per 100 000 in women potentially having the disease by the year 2050. The results of Liu and colleagues' sensitivity analysis excluding 2021 from model training projected ASIR among males flattening and showed much broader prediction intervals, while the trajectory for females remained similar to the investigators' main analysis.

Pronounced geographic disparities were also highlighted by Liu et al. East Asia and sub-Saharan Africa showed substantially lower disease estimates, the findings of which the team suggest likely impacted in part by the limited set of available data and possible under-ascertainment. Western Europe and North America showed the highest crude incidence (CIR) and crude prevalence (CPR) rates.

Incidence rates, both age- and sex-specific, were shown by the investigators to be similar among boys and girls in their childhood and adolescent years (ages 5 - 19 years), though disease incidence rose sharply with age among male subjects of the study. Liu and colleagues found this particularly to be the case in older age cohorts. A strong positive link between ASIR and SDI was noted as well (

Overall, the modeling study demonstrated a rise in the global burden of psoriasis between 1990 - 2021, aligning with previously-available data. These forecasts would indicate a continual rise in psoriasis incidence among both sexes through 2050, though Liu and coauthors found when they excluded 2021 from model fitting the projected increase for males to have diminished. This led to greater uncertainty, and the team noted the drivers of such sex-specific differences warrant further study.

The finding that psoriasis burden was greatest in high-income regions of the world such as North America and Western Europe was notable as well. The positive correlation between ASIR and SDI mirrors earlier reports, though country-level GBD data was noted by Liu et al as not fully accounting for various ecological confounders, including data availability and demographic composition.

Liu L, Wang R, Yu C, et al. Global Psoriasis Burden and Forecasts to 2050. JAMA Dermatol. Published online November 26, 2025. doi:10.1001/jamadermatol.2025.4572.

GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17. PMID: 38642570; PMCID: PMC11122111.

Psoriasis is projected to affect more individuals globally by 2050, with increasing incidence across various demographics and regions. Researchers, including Linli Liu, utilized data from the Global Burden of Disease Study 2021 to forecast these trends. The study highlighted significant geographic disparities, with lower estimates in East Asia and sub-Saharan Africa, and higher rates in Western Europe and North America. The analysis revealed a strong correlation between psoriasis incidence and the Sociodemographic Index. The study underscores the need for targeted public health strategies and further investigation into sex-specific differences.

This global analysis highlights the incidence of psoriasis around the world by 2025, noting various distinctions in region, age groups, and sex.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

Vinay Mehta, MD: Board-certified allergist/immunologist with Allergy & Asthma Associates of Southern California

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Credit: Allergy & Asthma Associates of Southern California

 can present uniquely in patients with skin of color, making timely recognition and effective management more challenging for clinicians. Classic signs such as erythema or inflammation may appear muted, harder to detect, or altogether different on darker skin tones, contributing to under-diagnosis, delayed treatment, and increased risk of pigmentary changes or scarring.

In this Q&A, Vinay Mehta, MD, a board-certified allergist/immunologist with Allergy & Asthma Associates of Southern California, discusses practical steps clinicians can take to better identify and manage AD in patients with skin of color. He highlights why traditional training materials often fall short, why dyspigmentation can be a critical clinical clue, and how simple adjustments, such as using alternative lighting or referencing more inclusive photo atlases, can sharpen diagnostic confidence.

How can clinicians more accurately recognize atopic dermatitis in patients with skin of color, given that erythema and inflammation may appear differently?

 One of the things I think would be helpful is to have atlas pictures. When in medical school and in residency and fellowship, we're used to seeing pictures, and I know there have been some initiatives to include more photos of patients of skin of color.

Erythema can be difficult to appreciate in patients who have darker skin, so what I typically do is I'll turn off the light. I'll use a flashlight so there's a better contrast, so I can better appreciate the erythema [and] dyspigmentation [hyperpigmentation and hypopigmentation]. These are often hallmarks of atopic dermatitis in patients of darker skin tone, which we sometimes don't recognize. [Another key distinction is] more extensor surfaces involvement.

We definitely need more training. We definitely need more examples, photos. I think that's helpful. Perhaps using social media. It's helpful to have real patients [with] skin [of] color, who have atopic dermatitis to just share their story. That will be very helpful in increasing awareness.

What practical steps can dermatologists take to improve diagnostic confidence and avoid underdiagnosis of atopic dermatitis in darker skin tones?

 I would like to see more studies. The more studies we have, the more information we have, the more we'll be able to appreciate some of the nuances and also see if certain molecules target better [in] this population compared to our typical white population.

What are the most effective strategies for building trust and improving adherence among patients of color with chronic skin conditions like atopic dermatitis?

 Listening through [stories] is very important to develop trust. Shared decision-making is also important. You really have to listen to their concerns… [to] understand their perspective, understand what is important to them.

: Can you discuss additional barriers to treating atopic dermatitis in patients with skin of color?

 There's health disparities in terms of access, especially in the minority population, in terms of what health insurance they have, in terms of access to care, and access to specialists.

Sometimes there may also be language barriers, particularly in the immigrant population. There may be cultural barriers as well, and so I think it's important to really spend time [with the patient].

Getting that trust [is important]. Once they trust you as a health care provider, it really improves adherence, and that goes a long way. These are chronic diseases, and there's no quick fix. Some of these therapies…have to be continued long term, and so that really requires good communication and a good relationship between the patient and the provider.

How can clinicians address pigmentation changes, scarring, and other post-inflammatory effects that are particularly concerning for patients with skin of color?

 Unfortunately, with atopic dermatitis, we do see that. We do see the pigmentation changes, hyperpigmentation or hypopigmentation. Perhaps in this case…start patients on systemic therapy, not wait until they have the scarring. In other words, move them from topicals to a systemic therapy, whether it's the biologic or an [oral JAK inhibitor] or something else. Move them quickly to prevent some of those side effects, those pigmentary changes.

This transcript has been edited for clarity.

Atopic dermatitis (AD) presents unique challenges in patients with skin of color due to differences in the appearance of erythema and inflammation, often leading to under-diagnosis and delayed treatment. Clinicians can improve diagnostic accuracy by using alternative lighting and inclusive photo atlases. Building trust through shared decision-making and addressing health disparities are crucial for effective management. Early intervention with systemic therapies can help prevent pigmentary changes and scarring. Enhanced training and research are needed to better understand and manage AD in diverse populations.

Board-certified allergist shares how clinicians can better recognize and prevent atopic dermatitis in patients with skin of color, addressing pigmentation.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Brandon Yan, MD, is a resident physician at the University of California.

Addressing Post-Pandemic Cardiovascular Mortality Rate Increases, With Brandon Yan, MD

 mortality trends in the US from 1999 to 2023, highlighting an abrupt increase in the wake of the COVID-19 pandemic.

From 1999 to 2023, age-adjusted mortality rates (AAMR) for CVD decreased from 350.8 to 218.3 deaths per 100,000, falling by 33.5%. These rates reached their lowest point in 2019, at 214.6 per 100,000. However, since the pandemic, mortality rates switched back, rising to 233.3 per 100,000 in 2021.

 spoke with Brandon Yan, MD, resident physician at the University of California and lead report author, to discuss the stark shift in mortality trends and what can be done to curtail them.

“Years of decline have plateaued overall, and it’s a very concerning plateau indeed, and we are still only beginning to learn why we’re not seeing continued progress,” Yan told 

 are large components of what we’re seeing here.”

During the analysis, Yan and colleagues analyzed death certificate data from the Wide-ranging Online Data for Epidemiologic Research (WONDER) database from the US Centers for Disease Control and Prevention, spotlighting the period from 1999 to 2023. CVD mortality was categorized into the following subtypes:

Conduction disorders and cardiac dysrhythmias

AAMRs were calculated using the 2000 US population as a standard, and CVD mortality was examined in 2 forms: underlying CVD cause or contributing CVD cause.

Yan and colleagues found that ischemic heart diseases saw a decline in mortality from 194.6 per 100,000 in 1999 to 88 in 2019, a decrease of 54.8%, but increased again to 92.8 in 2021 before declining again to 82.2 in 2023. Hypertensive diseases saw mortality double from 15.8 to 31.9 in 2023 and are now the fastest-growing underlying cause of cardiovascular death. Since 2022, hypertensive diseases have been the leading contributing cardiovascular cause of death.

Heart failure mortality initially declined from 20.3 in 1999 to 16.9 in 2011, but rose back to 21.6 in 2023, which was its highest recorded level. Cerebrovascular disease mortality fell from 61.6 in 1999 to 36.2 in 2013 but rose again to 37 in 2019 and to 39 in 2023. Finally, Yan and colleagues reported that aortic aneurysm and dissection mortality saw a 59% decrease during the study period alone.

Ultimately, Yan and colleagues noted that, while the immediate impact of the pandemic may have subsided, underlying trends that existed prior are still exerting influence. Ischemic heart disease mortality has begun to decrease again, responding to advancements in access to acute care and continuous efforts to manage risk factors. Through these methods, ischemic heart disease mortality has largely returned to its past levels despite sharp increases during the pandemic.

However, hypertensive disease mortality represents the opposite, having reached record heights and still rising. Yan and colleagues attribute this in part to lingering issues born of interrupted care during the pandemic, but also cite the struggle of addressing and maintaining chronic diseases.

The team called for public health interventions, spotlighting the importance of examining the long-term effects of the pandemic on chronic disease management. They also encouraged the strengthening of chronic disease surveillance and establishing easier and more equitable access to preventive care.

“I think we need a full-court press,” Yan said. “I would love for there to be a focus and investment in the prevention of heart disease from that population level. And I think a personalized approach is going to be very important as well. We’re seeing much more research on personalizing people’s risk factors for developing heart disease, atherosclerosis, and cardiovascular disease events. I think that’s going to be an important part of the equation as well.”

Editor's Note: Yan reports no relevant disclosures.

Yan BW, Arun AS, Curtis LH, et al. JACC Data Report. 

Journal of the American College of Cardiology

Wen J, Hu J, Zou G. Trends and differences in cardiovascular disease and alzheimer’s disease-related mortality among older adults in the United States, 1999 to 2023: A CDC wonder database analysis. 

American Heart Journal Plus: Cardiology Research and Practice

Videos

Yan discusses the reversion of 50-year trends in mortality and the steps needed to reduce these rates back to pre-pandemic levels.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Cardiomyopathy

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

2025 Society of Dermatology Physician Associates (SDPA) Fall Conference

 in San Antonio, Texas, a poster was presented titled 'Expert consensus recommendations on dermoscopy proficiency standards for physician assistants: results of a modified Delphi survey.'

This article highlighted a new expert consensus report proposing the first formal set of dermoscopy proficiency expectations for physician assistants (PAs). The report was authored by such investigators as Peter A. Young, MPAS, PA-C. Young and colleauges' report touched on the long-standing gap in dermatology and primary care education observed in a period in which PAs' role is expanding role in the skin cancer space.

Dermoscopy is now widely regarded as crucial for clinicians who assess the presence pigmented lesions and is being increasingly included in training within the dermatology field. The process is also gaining traction in primary care as melanoma and non-melanoma skin cancer rates continue to see increases around the country.

However, Young et al noted, despite the large number of PAs seeing patients across specialties, no agreed-upon dermoscopic learning objectives had been determined as guidelines for PA practices specifically. In this study, the investigative team sought to shift this paradigm.

There were 14 experienced dermoscopists gathered for this consensus panel, including 8 dermatologists and 6 PAs with backgrounds in consensus-building efforts for clinician dermoscopy benchmarks, standardized testing frameworks, and recommended PA competencies. Young and coauthors noted most participants had significant experience with the dermoscopy technique: 86% had implemented dermoscopy for over 12 years and there was a mean of 15.5 years of use.

A modified Delphi process was utilized for the group, combining 2 rounds of electronic surveys with a facilitated roundtable discussion following these surveys.

 Those included as panelists assessed dermoscopic expectations across 54 diagnoses. The experts were asked to determine which of various conditions represent foundational knowledge for PAs who are in the early-career period in primary care versus in dermatology.

By the second survey round, the experts were successful in attaining a consensus on 39 of the 54 diagnoses, or 72%, determining such diagnoses as appropriate for inclusion in PA educational materials.

 The remaining 28% of these were determined by the panel to be lower-priority items and not essential for beginners. Ultimately, the expert panel endorsed 14 key conditions for PAs practicing in primary care and 25 for those who work in dermatology, which Young and colleagues noted indicates a higher degree of diagnostic complexity expected in specialty settings.

The investigative team noted the strong interest in dermoscopy observed among those working as PAs. They highlighted prior national data indicating 77% of practicing PAs in all fields believe in the necessity of standard, formal dermoscopy instruction for their training. Dermatology-focused PA certification already involves dermoscopic content, but the team noted educators and supervising physicians lack guidance on which specific diagnoses constitute meaningful proficiency for those who are newer.

Overall, the expert consensus list generated through this study's process was designed to fill that void. As PAs continue to assume larger roles in dealing with patients showing suspicious lesions, the presence of shared dermoscopy training priorities may enhance diagnostic accuracy and even streamline collaboration among care teams.

Young and coauthors point to the potential of adopting these recommendations for professional organizations, training programs, and supervising dermatologists as leading to improved competence among PA trainees and early-career clinicians.

Young P, Middleton H, Seiverling E, et al. Expert consensus recommendations on dermoscopy proficiency standards for physician assistants: results of a modified Delphi survey. Presented at the Society of Dermatology Physician Associates (SDPA) Fall Conference, November 5-9, San Antonio, TX.

Lapides R, Saravi B, Roider E, et al. Possible Explanations for Rising Melanoma Rates Despite Increased Sunscreen Use over the Past Several Decades. Cancers (Basel). 2023 Dec 16;15(24):5868. doi: 10.3390/cancers15245868. PMID: 38136411; PMCID: PMC10741796.

A new expert consensus report has established the first formal dermoscopy proficiency standards for physician assistants (PAs), addressing a gap in dermatology and primary care education. The report, developed by a panel of experienced dermoscopists, utilized a modified Delphi process to identify key dermoscopic diagnoses for PA training. The consensus identified 14 essential conditions for PAs in primary care and 25 for those in dermatology, reflecting the complexity of specialty settings. This initiative aims to enhance diagnostic accuracy and collaboration among care teams, improving PA competence in skin cancer assessment.

This research, presented at the SDPA Fall Conference, highlights a consensus report proposing the first formal set of dermoscopy proficiency expectations for PAs.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs 

Marcus Shaker, MD, a professor of pediatrics and medicine at the Dartmouth Geisel School of Medicine

Screenshot 2025-11-06 at 10.12.42 AM.png

A quick guide for clinicians on epinephrine dosing, optimal observation periods, and the role of tryptase and other labs in anaphylaxis care.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Anaphylaxis Treatment FAQ: When to Give Epinephrine, Order Tests, Call 911

Michelle O'Donoghue, MD, is the McGillycuddy-Logue Endowed Chair in Cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School

O’Donoghue discusses the results of the recent OCEAN(a)-DOSE trial and addresses the implications for Lp(a)-lowering therapies moving forward.

Atherosclerotic Cardiovascular Disease

Dyslipidemia

Olpasiran Lowers Lp(a) Irrespective of Apo(a) Isoform Size, With Michelle O’Donoghue, MD

Yasmine Kirkorian, MD, is a dermatologist and chief of Dermatology at Children's National Hospital.

Kirkorian speaks in this interview about her sessions at SDPA Fall on genetic disorders in pediatric dermatology patients.

Guidelines on Genetic Disorders of the Skin and Pediatric Patients, With Yasmine Kirkorian, MD

Halpin reviews the state of triple therapy inhaler prescribing strategies in the era of new biologic options.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

COPD Inhaler Use in the Biologic Era, with David Halpin, MBBS, DPhil

Associate Professor, University of Alabama and Chief Medical Officer for AllerVie Clinical Research

Soong discussed the role of allergist's in atopic dermatitis care at a recent HCPLive clinical forum.

Shared Decisions, Better Outcomes in Atopic Dermatitis, With Weily Soong, MD

Explore the long-term safety and efficacy of JAK inhibitors in atopic dermatitis, enhancing patient care and clinician confidence.

Special Report: Safety, Future Directions, & the Art of Therapy Selection in Atopic Dermatitis

Healthcare providers discuss the importance of effective communication when switching patients from biologics to JAK inhibitors.

Special Report: Overcoming Therapeutic Inertia and Communicating Safety of  JAK Inhibitors

Special Report: Inadequate Response and When to Switch Systemic Therapy in Atopic Dermatitis

Explore the evolving landscape of atopic dermatitis treatment, focusing on advanced therapies and long-term patient management strategies.

Special Report: Treat-to-Target in Atopic Dermatitis—Applying the AHEAD Recommendations

Healthcare professionals explore effective questioning techniques to uncover deeper emotional and physical impacts of skin pain in patients.

Latest News

Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Addressing Post-Pandemic Cardiovascular Mortality Rate Increases, With Brandon Yan, MD

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs